RxDoctor Payments Data

Cynthia McGarvey, MD

Neurology · Indianapolis, INNPI 1134335870

Payments from drug & device makers

$26,795in general payments, 2019–2025

Across 1,695 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Novartis$1K
  • Jazz Pharmaceuticals Inc.$1K
  • Harmony Biosciences LLC$925
  • Eisai Inc.$896
  • plus $17K from 54 others

What the payments were for

  • Speaking & faculty fees$110%
  • Food & beverage$26,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)257$3,412
UCB, Inc.182$2,095
Novartis77$1,213
Jazz Pharmaceuticals Inc.45$1,116
Harmony Biosciences LLC51$925
Eisai Inc.45$896
Neurocrine Biosciences, Inc.48$890
Biogen49$875
Amgen(2 entities)44$864
Lilly USA, LLC84$828
AstraZeneca(2 entities)40$816
Supernus Pharmaceuticals, Inc.76$779
EMD Serono, Inc.40$762
Teva Pharmaceuticals USA, Inc.56$720
Argenx US, Inc.39$655
Sanofi31$653
Livanova USA, Inc.52$623
Bristol Myers Squibb33$607
MDD US Operations, LLC35$487
Alnylam Pharmaceuticals Inc.21$474
Sunovion Pharmaceuticals Inc.36$472
Pfizer38$467
Lundbeck LLC20$390
SK Life Science, Inc.17$386
Greenwich Biosciences, Inc.17$275
Johnson & Johnson(2 entities)14$264
Arbor Pharmaceuticals, Inc.14$249
Avadel CNS Pharmaceuticals, LLC11$244
TG Therapeutics, Inc.8$232
Biohaven Pharmaceutical Holding Company Ltd.14$209
Catalyst Pharmaceuticals, Inc.7$195
Upsher-smith Laboratories LLC10$185
Otsuka America Pharmaceutical, Inc.10$182
Amneal Pharmaceuticals LLC8$178
Genentech USA, Inc.8$164
Acadia Pharmaceuticals Inc11$162
Axsome Therapeutics, Inc.8$158
Tanabe Pharma America, Inc.7$152
Biohaven Pharmaceuticals, Inc.11$148
Vanda Pharmaceuticals Inc.6$136
Banner Life Sciences, LLC6$135
Ipsen Biopharmaceuticals, Inc8$135
Sumitomo Pharma America, Inc.7$127
Neurelis, Inc.5$125
Adamas Pharmaceuticals, Inc.6$109
Takeda Pharmaceuticals U.S.A., Inc.5$107
CSL Behring4$94
Springworks Therapeutics, Inc.4$94
Promius Pharma LLC5$91
Avanir Pharmaceuticals, Inc.6$88
Medtronic2$79
Cycle Pharmaceuticals Inc3$72
Assertio Therapeutics, Inc.5$70
Inspire Medical Systems, Inc.3$66
Scilex Pharmaceuticals Inc.4$66
Acorda Therapeutics, Inc3$64
Azurity Pharmaceuticals, Inc.3$63
Mallinckrodt Hospital Products Inc.2$61
Xeris Pharmaceuticals, Inc.3$57
Microtransponder, Inc.1$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,795 in reported general payments places this provider in the 80th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$204,991
Medicare patients
286
Services billed
17,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam32$71,713
Nurtec OdtRimegepant Sulfate31$55,390
AptiomEslicarbazepine Acetate26$51,272
Aimovig AutoinjectorErenumab-Aooe44$39,003
ReyvowLasmiditan Succinate30$23,129
Zembrace SymtouchSumatriptan Succinate12$17,733
BotoxOnabotulinumtoxina13$16,288
Keppra XrLevetiracetam13$13,348
Rufinamide12$9,066
Lacosamide47$7,582
Memantine Hcl113$4,088
DilantinPhenytoin Sodium Extended16$4,079
Duloxetine Hcl20$3,051
Memantine Hcl ErMemantine Hcl26$2,611
Levetiracetam51$2,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$2,095$71,71332 claims
PfizerNurtec Odt, Dilantin$467$59,46847 claims
Sunovion Pharmaceuticals Inc.Aptiom$472$51,27226 claims
Lilly USA, LLCReyvow$828$23,12930 claims
Upsher-smith Laboratories LLCZembrace Symtouch$185$17,73312 claims
AbbVieBotox$3,412$16,28813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →